Navigation Links
PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
Date:10/29/2008

ctions

-- Antidepressants: fluoxetine, prescribed to treat a variety of

conditions, including depression and other mental/mood disorders

-- Anti-anxiety medication: meprobamate, a treatment used to relieve

nervousness or tension that exceeds stress of everyday life

-- Painkillers: ibuprofen and naproxen

The new filtration data from PUR is particularly timely as many Americans are re-discovering tap water in an effort to offset the environmental impact and high cost of bottled water. While these intentions are good, a new survey from Procter & Gamble found that the majority of Americans are unaware that a wide range of pharmaceutical drugs have recently been detected in the tap water of certain cities across the country. Of this group, 94 percent say they would be "concerned" to learn that their tap water contained pharmaceuticals.

To date, scientists have found no evidence of adverse health effects by consumers exposed to trace amounts of pharmaceuticals in the water supply. "Naturally one would opt to have drinking water without pharmaceuticals in it," said Dr. Peter P. Rogers, Senior Advisor to Global Water Partnership, and professor of Environmental Engineering at Harvard University. "It is now confirmed that there is a point of use home filtration system that can reduce certain of these compounds as a safeguard before it becomes a potential issue."

Thought Leaders Gather to Discuss Water Issues

PUR's new filtration data was unveiled today at the "Giving Water a Voice" event in New York City. PUR joined the media with several leading water experts to discuss the various issues surrounding water both in the U.S. and globally. These experts included:

-- Dr. Peter P. Rogers, Senior Advisor to Global Water Partnership, and

professor of Environmental Engineering at Harvard University

-- Elizabeth Rogers, Founder of Shift Your Habit environmental consulting

gro
'/>"/>

SOURCE Procter & Gamble
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Water Picks Up Odor From Plastic Pipes
2. AUDIO from Medialink and Kelloggs: Whats in Your Water?
3. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
4. Briefing on a new Web resource to address global drinking water crisis
5. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
6. New Herbal Water Creating Taste Sensation: Ayalas Herbal Water Has No Calories, No Preservatives and No Artificial Additives. Just All the Natural Benefits of Herbs!
7. Out of the woods: Physicians get urban disaster training in forests, gorges and waters
8. Milestone Scientific to Present at the Edgewater Research Investor Conference
9. After Infant Gripe Water Recall Scare, Homeopathic Medicine Offers Safe Alternative
10. AWWA Water 101 Seminar Targets Sales, Marketing and PR Pros
11. New Fish Advice Throws Baby Out With the Bath Water, Says Mercury Watchdog Group
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 1NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 2NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 3Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 1Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 2Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 3Gene Therapy Brings New Muscle to Monkeys 61251 1
Other Medicine Technology:Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 2Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 3Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 4Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 6